36 results match your criteria: "The Fourth Affiliated Hospital of Nantong Medical College[Affiliation]"

Upregulation of the B7/CD28 family member B7-H3 in bladder cancer.

Oncol Lett

March 2015

Department of Urology, The Fourth Affiliated Hospital of Nantong Medical College, Yancheng City No. 1 People's Hospital, Yancheng, Jiangsu 224001, P.R. China.

Dysregulation of B7-H3 has been observed in a variety of types of human cancers. In the present study, the mRNA expression level of B7-H3 was analyzed in bladder cancer by performing semi-quantitative reverse transcription-polymerase chain reaction on clinical specimens from transitional cell carcinomas (TCCs) and their normal adjacent tissues (NATs). Immunohistochemical analysis was performed to compare the protein expression level of B7-H3 in TCCs and the paired NATs.

View Article and Find Full Text PDF

MicroRNA-133a inhibits cell proliferation, colony formation ability, migration and invasion by targeting matrix metallopeptidase 9 in hepatocellular carcinoma.

Mol Med Rep

May 2015

Department of Infectious Diseases, The Fourth Affiliated Hospital of Nantong Medical College, Yancheng No. 1 People's Hospital, Yancheng, Jiangsu 224001, P.R. China.

MicroRNA‑133a (miR‑133a) is downregulated in various types of human malignancy, including hepatocellular carcinoma (HCC), renal cell carcinoma, esophageal squamous cell carcinoma, bladder cancer, ileal carcinoid and rhabdomyosarcoma. The aim of the present study was to examine the effects of miR‑133a on HCC cell proliferation, colony formation, migration and invasion. miR‑133a was transfected into the HCC HepG2 and SMMC‑7721 cell lines and the expression levels of miR‑133a were determined; in addition, cell viability assays, colony formation assays, cell migration assays, cell invasion assays, western blot analyses and luciferase assays were performed in the HCC cell lines.

View Article and Find Full Text PDF

microRNA‑99a (miR‑99a) was reported to be among the most frequently downregulated miRNAs in numerous types of human cancers, including prostate, bladder, hepatocellular and ovarian carcinoma, squamous cell carcinoma of the tongue, squamous cell lung carcinoma as well as childhood adrenocortical tumors. The aim of the present study was to determine the effects of miRNA‑99a on cell proliferation, colony formation ability, migration and invasion in prostate cancer. Following transfection with miRNA‑99a, cell viability, colony formation, cell migration and cell invasion assays were performed on prostate cancer cell lines, as well as western blot analysis and luciferase assays.

View Article and Find Full Text PDF

microRNA-99a inhibiting cell proliferation, migration and invasion by targeting fibroblast growth factor receptor 3 in bladder cancer.

Oncol Lett

April 2014

Department of Urology, The Fourth Affiliated Hospital of Nantong Medical College, Yancheng City No. 1 People's Hospital, Yancheng, Jiangsu 224001, P.R. China.

The expression of microRNA-99a (miRNA-99a) has been investigated in a number of human cancers. It has been reported to be downregulated in several types of cancer, including ovarian carcinoma, squamous cell carcinoma of the tongue, squamous cell lung carcinoma, hepatocellular carcinoma, bladder cancer, prostate cancer and childhood adrenocortical tumors. In the present study, the effects of miRNA-99a on bladder cancer cell proliferation, migration and invasion were examined.

View Article and Find Full Text PDF

microRNA‑145 inhibits cell proliferation, migration and invasion by targeting matrix metallopeptidase-11 in renal cell carcinoma.

Mol Med Rep

July 2014

Department of Urology, The Fourth Affiliated Hospital of Nantong Medical College, Yancheng City No. 1 People's Hospital, Yancheng, Jiangsu 224001, P.R. China.

microRNA‑145 (miR‑145) has been reported to be frequently downregulated in various types of cancer, including renal, prostate, bladder, lung and colon cancer, as well as B‑cell malignancies. The present study examined the effects of miR‑145 on the cell proliferation, migration and invasion of renal cell carcinoma (RCC). Following transfection of miR‑145, an MTT, cell migration, cell invasion and luciferase assays, and western blot analysis were conducted in RCC cell lines.

View Article and Find Full Text PDF

microRNA (miRNA)-133b has been revealed to be downregulated in head and neck/oral, bladder, human non-small cell lung, colorectal and esophageal squamous cell cancer. The present study examined the expression of miR-133b in renal cell carcinoma (RCC) cell lines and the effects of miRNA-133b on RCC cell proliferation, migration and invasion. Quantitative polymerase chain reaction was used to detect the expression of miR-133b in RCC cell lines.

View Article and Find Full Text PDF

MicroRNA-143 inhibits cell migration and invasion by targeting matrix metalloproteinase 13 in prostate cancer.

Mol Med Rep

August 2013

Department of Urology, The Fourth Affiliated Hospital of Nantong Medical College, Yancheng City No. 1 People's Hospital, Yancheng, Jiangsu 224001, P.R. China.

MicroRN-143 (miR‑143) has been previously reported to be downregulated in specific types of cancer, including colorectal, bladder, oral squamous cell, pituitary, cervical, nasopharyngeal, lymphoma and prostate cancer. In the present study, the effects of miR-143 on prostate cancer cell migration and invasion were examined. Following transfection with miR-143, miR-143 expression, cell migration and invasion assays, luciferase assay and western blot analysis were conducted in prostate cancer cell lines.

View Article and Find Full Text PDF

The expression of microRNA-125b (miR-125b) has been investigated in many human cancers. It has been demonstrated to be downregulated in certain types of cancer, such as bladder cancer, thyroid anaplastic carcinomas, squamous cell carcinoma of the tongue, hepatocellular carcinoma, ovarian and breast cancer. In the present study, we examined the effects of miR-125b on bladder cancer cell migration and invasion.

View Article and Find Full Text PDF

Interleukin-11, an interleukin-6-like cytokine, is a promising predictor for bladder cancer prognosis.

Mol Med Rep

February 2013

Department of Urology, The Fourth Affiliated Hospital of Nantong Medical College, Yancheng City No. 1 People's Hospital, Nanjing, P.R. China.

Numerous studies have suggested that interleukin 11 (IL-11) has roles in human gastric, prostate and bone cancer and endometrial carcinoma. Hence, we evaluated the expression of IL-11 in bladder cancer and the correlation of IL-11 levels and clinico-pathological features. The expression of IL-11 in primary human bladder cell culture, human bladder cancer cell lines, transitional cell carcinoma (TCC) and non-cancerous bladder tissues (NATs) were analyzed by western blotting.

View Article and Find Full Text PDF

Downregulation of Dicer, a component of the microRNA machinery, in bladder cancer.

Mol Med Rep

March 2012

Department of Urology, The Fourth Affiliated Hospital of Nantong Medical College, Yancheng City No 1 People's Hospital, Nanjing, Jiangsu, PR China.

Dysregulation of microRNA metabolism has been observed in a variety of human cancers. In this study, we evaluated the expression of the enzymes of the machinery Dicer, Drosha and DGCR8, in transitional cell carcinomas (TCCs) of the urinary bladder. The expression of Dicer, Drosha and DGCR8 was analyzed using semi-quantitative RT-PCR in clinical specimens from normal bladder mucosa, TCCs and their normal adjacent tissues (NATs).

View Article and Find Full Text PDF

Effect of nonoperative treatment on the outcome of patients with posttraumatic hydrocephalus.

Chin J Traumatol

February 2002

Department of Neurosurgery, The Fourth Affiliated Hospital of Nantong Medical College, The First People's Hospital of Yancheng, Yancheng 224001, China.

Objective: To compare the outcome of non-operative treatment with the outcome of surgical intraventricular drainage for patients with posttraumatic hydrocephalus including complications, mortality and favorable outcome.

Methods: Thirty-nine patients were assigned to a nonoperative treatment group and 38 patents to a surgical intraventricular drainage group. Each patient's outcome was evaluated 3 years after treatment by using Glasgow Outcome Scale.

View Article and Find Full Text PDF